
|Articles|January 28, 2022
What’s New?
Acne patients are benefitting from a robust pipeline with treatments that hold promise for increased efficacy and safety. First-in-class additions to the FDA-approved armamentarium, such as the novel antiandrogen clascoterone (Winlevi; Sun Pharma), give dermatologists and pediatricians new tools to combat this skin condition. Speakers offer insights on matching medications to individual patient needs and controlling costs.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Pediatric clinical trials update: May 2026
2
Simple screening questions may help pediatricians identify hidradenitis suppurativa earlier
3
How to recognize and when to refer for children with hidradenitis suppurativa
4
Jamie Wood, MD, on the significance of the Afrezza approval for pediatric diabetes
5

